Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Updated FIERCE-22 data: vofatamab with pembrolizumab for mUC

Arlene Siefker-Radtke • 28 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Antibodies Pembrolizumab Vofatamab
FIERCE-22

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the updated interim analysis of FIERCE-22 (NCT03123055). This trial is testing the exciting double immunotherapy combination of vofatamab with pembrolizumab in metastatic urothelial carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals